Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Boehringer Ingelheim
Express Scripts
AstraZeneca
Baxter

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LY2157299

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LY2157299?

LY2157299 is an investigational drug.

There have been 23 clinical trials for LY2157299. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Pancreatic Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, The Netherlands Cancer Institute, and Vanderbilt-Ingram Cancer Center.

There are five US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for LY2157299
TitleSponsorPhase
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAgendiaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAzienda Ospedaliera Niguarda Cà GrandaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerCatalan Institute of HealthPhase 1/Phase 2

See all LY2157299 clinical trials

Clinical Trial Summary for LY2157299

Top disease conditions for LY2157299
Top clinical trial sponsors for LY2157299

See all LY2157299 clinical trials

US Patents for LY2157299

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2157299   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2157299   Start Trial Quinolinyl-pyrrolopyrazoles Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2157299   Start Trial TGF-.beta. inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY2157299   Start Trial Compositions and methods for treating and preventing neointimal stenosis Yale University (New Haven, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY2157299

Drugname Country Document Number Estimated Expiration Related US Patent
LY2157299 Austria 341550 2022-11-22   Start Trial
LY2157299 Australia 2003291643 2022-11-22   Start Trial
LY2157299 Brazil 0315337 2022-11-22   Start Trial
LY2157299 Canada 2501322 2022-11-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
McKinsey
Colorcon
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.